-- Knight Therapeutics (GUD.TO) has received regulatory approval from the Brazil health authorities for Tavalisse (fostamatinib disodium hexahydrate), the company said on Friday.
Tavalisse is prescribed for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Tavalisse is expected to launch in Brazil in the second half of this year.
Knight Therapeutic shares closed up $0.84, to $8.35 on Thursday on the Toronto Stock Exchange.